glycine has been researched along with Lymphoma, Follicular in 1 studies
Lymphoma, Follicular: Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ixazomib is an investigational proteasome inhibitor that has shown preclinical activity in lymphoma models." | 2.79 | Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. ( Assouline, SE; Chang, J; Cheson, BD; Di Bacco, A; Gupta, N; Hamburg, S; Hui, AM; Martin, P; Reyes, R; Rifkin, R; Shou, Y; Yu, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Assouline, SE | 1 |
| Chang, J | 1 |
| Cheson, BD | 1 |
| Rifkin, R | 1 |
| Hamburg, S | 1 |
| Reyes, R | 1 |
| Hui, AM | 1 |
| Yu, J | 1 |
| Gupta, N | 1 |
| Di Bacco, A | 1 |
| Shou, Y | 1 |
| Martin, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic[NCT03683277] | Phase 2 | 26 participants (Actual) | Interventional | 2019-11-03 | Terminated (stopped due to Recruitment issue, 26 patients enrolled instead of 70 initially planned) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for glycine and Lymphoma, Follicular
| Article | Year |
|---|---|
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
Topics: Adult; Aged; Boron Compounds; Diarrhea; Female; Glycine; Humans; Lymphoma, Follicular; Lymphoma, T-C | 2014 |